Neurosurgery Shaanxi Provincial People's Hospital, Xi'an, China.
Medical College of Nantong University, Nantong, China.
Front Immunol. 2022 Jun 21;13:799509. doi: 10.3389/fimmu.2022.799509. eCollection 2022.
Glioblastoma multiforme (GBM) has been identified as a frequently occurring adult primary brain cancer that is highly aggressive. Currently, the prognostic outcome for GBM patients is dismal, even with intensive treatment, and the median overall survival (OS) is 14.6 months. Immunotherapy, which is specific at the cellular level and can generate persistent immunosurveillance, is now becoming a promising tool to treat diverse cancers. However, the complicated nature of the tumor microenvironment (TME) makes it challenging to develop anti-GBM immunotherapy because several cell types, cytokines, and signaling pathways are involved in generating the immunosuppressive environment. Novel immunotherapies can illustrate novel tumor-induced immunosuppressive mechanisms. Here, we used unsupervised clustering analysis to identify different subtypes of immune cell infiltration that actuated different prognoses, biological actions, and immunotherapy responses. Gene cluster A, with a hot immune cell infiltration phenotype, had high levels of immune-related genes (IRGs), which were associated with immune pathways including the interferon-gamma response and interferon-alpha response, and had low and mutation frequencies. Gene cluster B, a cold immune cell infiltration subtype, exhibited a high expression of the , , , , , , , , , , , , , , and genes and a low expression of immune-related genes, i.e., low levels of immune reactivity. Our study highlighted the complex interplay between immune cell infiltration and genetic mutation in the establishment of the tumor immune phenotype. Gene cluster A was identified as an important subtype with a better prognosis and improved immunotherapy response.
多形性胶质母细胞瘤(GBM)已被确定为一种常见的成人原发性脑癌,其侵袭性很强。目前,即使经过强化治疗,GBM 患者的预后仍不容乐观,中位总生存期(OS)为 14.6 个月。免疫疗法在细胞水平上具有特异性,可以产生持续的免疫监视,现已成为治疗多种癌症的有前途的工具。然而,肿瘤微环境(TME)的复杂性使得开发抗 GBM 免疫疗法具有挑战性,因为有几种细胞类型、细胞因子和信号通路参与产生免疫抑制环境。新的免疫疗法可以阐明新的肿瘤诱导免疫抑制机制。在这里,我们使用无监督聚类分析来识别不同类型的免疫细胞浸润,这些浸润激活了不同的预后、生物学作用和免疫治疗反应。基因簇 A 具有热免疫细胞浸润表型,具有高水平的免疫相关基因(IRGs),与包括干扰素-γ反应和干扰素-α反应在内的免疫途径相关,且具有低 和 突变频率。基因簇 B 是一种冷免疫细胞浸润亚型,其 、 、 、 、 、 、 、 、 、 、 、 、 和 基因表达水平较高,而免疫相关基因表达水平较低,即免疫反应性较低。我们的研究强调了免疫细胞浸润和遗传突变在肿瘤免疫表型形成中的复杂相互作用。基因簇 A 被确定为一个重要的亚型,具有更好的预后和改善的免疫治疗反应。